A lipid nanoparticle composition and a pharmaceutical composition for treating a hematoproliferative disorder
AssigneeJiangsu Genalza Biotech Co., Ltd.
InventorsHao Feng, Yibai Li
Life of this patent
Estimating the term…
Abstract
The present invention provides a lipid nanoparticle composition and a pharmaceutical composition thereof used in treating a hematoproliferative disorder. Specifically, the lipid nanoparticle composition may include cytarabine, an anthracycline, and lipid nanoparticles, wherein cytarabine and the anthracycline are co-encapsulated in the lipid nanoparticles, the lipid nanoparticles comprise a charged lipid stabilizer, and the effective mean particle size of the lipid nanoparticles is less than 400 nm.
Claims24
A lipid nanoparticle composition, comprising:
- cytarabine, an anthracycline, and lipid nanoparticles, wherein
- cytarabine and the anthracycline are co-encapsulated in the lipid nanoparticles,
- the lipid nanoparticles comprise a charged lipid stabilizer, and
- the effective mean particle size of the lipid nanoparticles is less than 400 nm.
A method of treating a hematoproliferative disorder, comprising administrating an effective amount of the lipid nanoparticle composition of claim to a subject in need thereof;
- wherein
- the hematoproliferative disorder is at least one of leukemia, malignant lymphoma, or multiple myeloma.
(canceled)
Dependencies are inferred from the claim text.